LUMOS PHARMA, INC. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019
Cash Flows From Operating Activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation
Depreciation and amortization
Gain on sale of priority review voucher
Loss on sale or disposal of fixed assets
Amortization of right-of-use assets and change in operating lease liability
Impairment of fixed assets
Loss on sale of fixed assets
In-process research and development charge
Benefit for deferred taxes
Other income, net

Changes in operating assets and liabilities:
Prepaid expenses and other current assets
Other receivables
Accounts payable and accrued expenses
Income taxes receivable, net
Unearned revenue
Deferred rent

Net cash used in operating activities
Cash Flows From Investing Activities
Proceeds on sale of equipment
Cash acquired in connection with merger
Final installment from sale of priority review voucher
Purchases of marketable securities
Maturities of marketable securities
Purchase of equipment
Net cash provided by (used in) investing activities

Cash Flows From Financing Activities
Exercise of stock options
Sale of shares under stock purchase plans
Issuance of common stock under share-based compensation plans
Payment for tax withholding on vested awards
Repurchases of common stock
Sale of shares under Controlled Equity OfferingSM, net of costs
Payment of offering costs under Controlled Equity OfferingSM
Principal payments on notes payable
Net cash used in financing activities

Net decrease in cash and cash equivalents
Cash and cash equivalents at beginning of year
Cash and cash equivalents at end of year
Cash received for income taxes
Cash paid for interest
Cash paid for taxes
Conversion of preferred stock to common stock
Issuance of common stock to NewLink shareholders
Non-cash settlement of liability related to priority review voucher

Comments